TrialJournal of neurology2025

Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study.

Soe Mar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.